Goldberg Michael sold $1.1M of CDNA
Goldberg Michael sold 13,800 shares of CareDx, Inc. (CDNA) at an average of $79.15 ($78.32–$79.85, $1.09M total) across 3 trades on 2026-11-12 under a Rule 10b5-1 trading plan.
CareDx, Inc.
CareDx is a precision medicine company serving transplant patients, clinicians and transplant centers. It provides non-invasive molecular testing for heart, kidney and lung transplant recipients, along with laboratory products, digital health technologies, patient support and specialized pharmacy services. Its commercial testing services include AlloMap Heart and AlloSure tests for transplant surveillance, as well as testing for hematopoietic cell transplant recipients and cell therapy patients. Laboratory products help match organ or stem cell donors with recipients and support post-transplant monitoring. Digital and patient offerings include transplant workflow and referral software, quality and waitlist support, medication adherence tools, remote monitoring and pharmacy care. CareDx earns money by providing testing services, selling laboratory products and software, and offering pharmacy and other patient and center services. It also partners with pharmaceutical and biopharmaceutical companies on testing and research. The company operates as one reportable segment and is headquartered in Brisbane, California, with other primary operations in Omaha, Nebraska, and Stockholm, Sweden.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Goldberg Michael sold 13,800 shares of CareDx, Inc. (CDNA) at an average of $79.15 ($78.32–$79.85, $1.09M total) across 3 trades on 2026-11-12 under a Rule 10b5-1 trading plan.
Piper Sandler initiated coverage on CareDx (CDNA) with an overweight rating and $100 price target, citing growth potential. The stock trades at $80.77, up 382% over the past year. The firm expects mid-teens to 20% growth in transplant business and 30%-40% annual growth for NavDx. CareDx reported Q3 2026 earnings of $0.70 EPS and $139M revenue, raising its full-year outlook. BTIG and Canaccord also raised their price targets to $92 and $99, respectively, maintaining Buy ratings.
Kennedy Keith (CFO & COO) sold 61,961 shares of CareDx, Inc. (CDNA) at an average of $77.82 ($76.55–$83.60, $4.82M total) across 8 trades on 2026-11-05 under a Rule 10b5-1 trading plan.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning CDNA (CareDx, Inc.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent CDNA coverage spans financial news, earnings and insider activity.
In the last 30 days, CDNA insiders filed 16 SEC Form 4 transactions — no purchases and 16 sales ($6.4M). The most active reporter was Kennedy Keith, CFO & COO, with 10 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Insider selling is a modest negative signal, but the 10b5-1 structure reduces interpretability as a directional bet.
Analyst upgrade to overweight with a higher price target may drive buying interest.
The insider sale may signal reduced confidence from the CFO, creating short‑term selling pressure.
No immediate price catalyst; the piece is a qualitative outlook.
Positive analyst upgrade based on rising earnings estimates.
AlphAI scores every news story that mentions CDNA with an AI model for sentiment and relevance, and aggregates insider trades from CareDx, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Goldberg Michael sold 13,800 shares of CareDx, Inc. (CDNA) at an average of $79.15 ($78.32–$79.85, $1.09M total) across 3 trades on 2026-11-12 under a Rule 10b5-1 trading plan.
Piper Sandler initiated coverage on CareDx (CDNA) with an overweight rating and $100 price target, citing growth potential. The stock trades at $80.77, up 382% over the past year. The firm expects mid-teens to 20% growth in transplant business and 30%-40% annual growth for NavDx. CareDx reported Q3 2026 earnings of $0.70 EPS and $139M revenue, raising its full-year outlook. BTIG and Canaccord also raised their price targets to $92 and $99, respectively, maintaining Buy ratings.
Kennedy Keith (CFO & COO) sold 61,961 shares of CareDx, Inc. (CDNA) at an average of $77.82 ($76.55–$83.60, $4.82M total) across 8 trades on 2026-11-05 under a Rule 10b5-1 trading plan.
CareDx's fair value suggests a 19% potential upside, with some analysts projecting even higher gains. Bullish forecasts include revenue of $673.2M and earnings of $58.7M by 2029, differing from consensus estimates. Investors are advised to review multiple viewpoints and consider key rewards and warning signs.
CareDx (CDNA) was upgraded to a Zacks Rank #1 (Strong Buy) due to an upward trend in earnings estimates, which could positively impact its stock price. The company is expected to earn $1.73 per share for the fiscal year ending December 2026, with the Zacks Consensus Estimate increasing 110.6% over the past three months. The upgrade places CareDx in the top 5% of Zacks-covered stocks.
CareDx published a study involving 1,137 kidney transplant recipients, finding early AlloSure measurements correlated with 3-year outcomes. The company did not provide prior-period comparisons.
CareDx's stock surged 22% after Q3 results beat expectations, with revenue up 39% to $139.4M and adjusted earnings at 70 cents per share. The company raised its 2026 revenue guidance to $520M-$530M. Growth was driven by a 65% increase in testing services revenue, boosted by the Naveris acquisition. The stock closed at $87.41, with a market value of $4.6B.
ARK ETFs sold 17,626 shares of Eli Lilly (LLY) for $24.2M and bought shares in Tempus AI (TEM) for $12M, Coinbase (COIN) for $6.3M, Circle (CRCL) for $6M, Pacific Biosciences (PACB) for $1.4M, and Robinhood (HOOD) for $1.3M. They also sold shares in Bullish (BLSH) for $6.8M and CareDx (CDNA) for $3.6M.
CareDx, Inc.'s average stock price target increased to $86.17 from $65.33, with estimates ranging from $46 to $100 per share. This implies a 20% upside based on the Oct. 29 closing price. The consensus rating remains 'Buy' among 7 analysts, with 5 Buys and 2 Holds.
Healthcare stocks rose after earnings reports. CareDx (CDNA) gained 20% on strong Q3 revenue growth and raised FY26 guidance. Regeneron (REGN) advanced 12% with 36% revenue growth. Profound Medical (PROF) climbed 10% on a new distribution deal. AstraZeneca (AZN) rose 7% with higher Q3 profit and maintained FY26 outlook.